Xvivo Perfusion AB (publ) (XVIVO)
Free
No email, no account, no signup.
Pulling latest news for Xvivo Perfusion AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Organ perfusion and preservation
Market Cap
$928M
We're already tracking Xvivo Perfusion AB (publ) — here are the latest events we've registered
Recent News
- On April 22, 2026, XVIVO announced positive results from the HOPE-at-Heart clinical trial for heart preservation using the XVIVO Heart Assist Transport. The company reported record Q1 2026 net sales of SEK 241 million on April 23, 2026. At the Annual General Meeting on April 27, 2026, shareholders resolved to re-elect the board and carry forward profits without a dividend.
Want to know how this news affects Xvivo Perfusion AB (publ)? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Xvivo Perfusion AB (publ) will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.